Levetiracetam Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antiepileptic
Subclass
Pyrrolidone derivative
Speciality
Neurology
Schedule (India)
Schedule H
Routes
Oral, Intravenous
Formulations
- Tablets (Immediate-Release): 250 mg, 500 mg, 750 mg, 1000 mg
- Extended-Release Tablets: 500 mg, 750 mg, 1000 mg
- Oral Solution: 100 mg/mL
- Injection (IV): 500 mg/5 mL (100 mg/mL)
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Focal (Partial-Onset) Seizures — with or without secondary generalisation
Adults — Monotherapy or Adjunctive Therapy:
| Parameter | Recommendation |
|---|---|
| Starting dose | 500 mg orally twice daily |
| Titration | Increase by 500 mg twice daily every 2 weeks based on response and tolerability |
| Usual maintenance dose | 1000–3000 mg/day in 2 divided doses |
| Maximum dose | 3000 mg/day |
Clinical Notes:
- May be used as monotherapy or adjunctive therapy
- IV formulation bioequivalent to oral — same dose, administer over 15 minutes
- Extended-release tablets allow once-daily dosing in stable patients
2. Myoclonic Seizures in Juvenile Myoclonic Epilepsy
Adults — Adjunctive Therapy Only:
| Parameter | Recommendation |
|---|---|
| Starting dose | 500 mg orally twice daily |
| Titration | Increase by 500 mg twice daily every 2 weeks |
| Usual maintenance dose | 1000–3000 mg/day in 2 divided doses |
| Maximum dose | 3000 mg/day |
Clinical Notes:
- Approved only as adjunctive therapy — not for monotherapy in myoclonic seizures
- Age ≥12 years for this indication
3. Primary Generalised Tonic-Clonic Seizures in Idiopathic Generalised Epilepsy
Adults — Adjunctive Therapy:
| Parameter | Recommendation |
|---|---|
| Starting dose | 500 mg orally twice daily |
| Titration | Increase by 500–1000 mg/day every 2–4 weeks |
| Usual maintenance dose | 1000–3000 mg/day in 2 divided doses |
| Maximum dose | 3000 mg/day |
Clinical Notes:
- Effective for generalised tonic-clonic seizures in idiopathic generalised epilepsy
- Age ≥12 years for this indication
4. Intravenous Use — When Oral Administration Not Feasible
| Parameter | Recommendation |
|---|---|
| Dose | Same as oral dosing — 1:1 dose equivalence |
| Administration | Dilute in NS/D5W/RL and infuse over 15 minutes |
| Duration of IV use | Transition to oral as soon as feasible |
Secondary Indications – Adults Only (Off-label)
| Indication | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|
|
Status Epilepticus — Adjunctive Therapy — OFF-LABEL
|
Loading: 1000–3000 mg IV over 15 minutes; Maintenance: 500–1500 mg BD | Until seizure control achieved and oral transition possible | Specialist/ICU only | Indian tertiary hospital protocols; supportive RCTs |
|
Post-Traumatic Seizure Prophylaxis — OFF-LABEL
|
500 mg BD starting within 24 hours of injury | 7 days post-injury (short-term prophylaxis only) | Neurosurgery/Critical Care | AIIMS protocols; international RCTs |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications: Focal Seizures, Myoclonic Seizures, Generalised Tonic-Clonic Seizures
Age Restriction: Not recommended below 1 month of age. Use below 6 months only under specialist paediatric neurology supervision.
Weight-Based Dosing Table
| Age Group | Starting Dose | Titration | Usual Maintenance | Maximum Dose |
|---|---|---|---|---|
| 1–6 months | 7 mg/kg orally twice daily | Increase by 7 mg/kg BD every 2 weeks | 21 mg/kg twice daily | 42 mg/kg/day |
| 6 months – <4 years | 10 mg/kg orally twice daily | Increase by 10 mg/kg BD every 2 weeks | 25 mg/kg twice daily | 50 mg/kg/day |
| 4 – <16 years | 10 mg/kg (max 250 mg) orally twice daily | Increase by 10 mg/kg BD every 2 weeks | 30 mg/kg twice daily | 60 mg/kg/day (max 3000 mg/day) |
| ≥16 years | Adult dosing applies | — | — | 3000 mg/day |
Formulation Notes:
- Use oral solution (100 mg/mL) for accurate weight-based dosing in younger children
- Tablets appropriate for children ≥20 kg who can swallow whole tablets
- IV dosing same as oral — infuse over 15 minutes
Safety Monitoring:
- Monitor for behavioural changes (irritability, aggression, mood swings)
- Assess sedation and psychomotor development
- Educate caregivers about behavioural adverse effects
Secondary Indications – Paediatric (Off-label)
| Indication | Dose | Notes | Evidence Basis |
|---|---|---|---|
|
Adjunctive therapy in Dravet Syndrome — OFF-LABEL
|
Individualised; often 20–40 mg/kg/day | Specialist only; usually combined with valproate or clobazam | Indian paediatric neurology practice |
|
Neonatal Seizures — OFF-LABEL
|
Loading: 20–40 mg/kg IV; Maintenance: 10–30 mg/kg BD | NICU setting only; specialist supervision mandatory | Tertiary NICU protocols |
Renal Adjustments
Levetiracetam is primarily renally excreted — dose reduction required in renal impairment:
| eGFR (mL/min/1.73 m²) | Recommended Dose |
|---|---|
| ≥80 | No adjustment — standard dosing |
| 50–79 | 500–1000 mg twice daily |
| 30–49 | 250–750 mg twice daily |
| <30 (not on dialysis) | 250–500 mg twice daily |
| ESRD on haemodialysis | 500–1000 mg once daily; give supplemental dose of 250–500 mg after each dialysis session |
Notes:
- Use oral solution for precise dose titration in severe impairment
- Peritoneal dialysis: limited data; use haemodialysis recommendations as guide
Hepatic adjustment
Contraindications
- Known hypersensitivity to levetiracetam, other pyrrolidone derivatives, or any excipient
- History of severe psychiatric reaction (psychosis, severe aggression) attributable to levetiracetam — relative contraindication; avoid rechallenge
Cautions
- Pre-existing psychiatric disorders (depression, anxiety, psychosis) — risk of exacerbation
- History of behavioural disturbances — increased risk of irritability and aggression
- Suicidal ideation risk — monitor mood, especially in adolescents and young adults
- Renal impairment — dose adjustment mandatory
- Elderly with cognitive impairment — enhanced CNS sensitivity
- Abrupt withdrawal — taper gradually over 2–4 weeks to avoid rebound seizures
- Driving and operating machinery — advise caution due to somnolence risk
Pregnancy
| Parameter | Details |
|---|---|
| Risk category | Relatively low teratogenic risk compared to older AEDs (valproate, phenytoin, carbamazepine) |
| Preferred alternatives | Levetiracetam or lamotrigine preferred in Indian obstetric/neurology practice when AED required |
| When may be used | May be continued in pregnancy if seizure control established; avoid switching AEDs during pregnancy if possible |
| Monitoring | Folic acid 5 mg/day from preconception through first trimester; monitor maternal seizure control; targeted anomaly scan; monitor drug levels (clearance increases in pregnancy) |
| Neonatal concerns | Monitor neonate for withdrawal symptoms (rare); vitamin K prophylaxis as standard |
Lactation
| Parameter | Details |
|---|---|
| Compatibility | Compatible with breastfeeding |
| Drug levels in milk | Low to moderate (infant receives approximately 3–8% of maternal weight-adjusted dose) |
| Preferred alternatives | Levetiracetam is among preferred AEDs for lactating women; lamotrigine also acceptable |
| Infant monitoring | Observe for sedation, irritability, poor feeding, weight gain; monitor developmental milestones |
Elderly
| Parameter | Recommendation |
|---|---|
| Starting dose | 250 mg twice daily |
| Titration | Slower titration — increase by 250 mg twice daily every 2 weeks |
| Special risks | Increased risk of somnolence, dizziness, falls, cognitive impairment; higher prevalence of occult renal impairment — check eGFR before dosing |
| Formulation | Oral solution preferred for flexible dose adjustment |
Major drug interactions
| Drug/Class | Mechanism/Effect | Recommendation |
|---|---|---|
| Methotrexate | Levetiracetam may reduce renal clearance of methotrexate → increased methotrexate toxicity | Monitor for methotrexate toxicity (mucositis, myelosuppression); consider dose adjustment |
| CNS depressants (benzodiazepines, opioids, sedating antihistamines) | Additive CNS depression | Use cautiously; monitor for excessive sedation |
Note: Levetiracetam does not induce or inhibit CYP450 enzymes — minimal hepatic drug interaction potential.
Moderate drug interactions
| Drug/Class | Effect | Recommendation |
|---|---|---|
| Carbamazepine | Minor pharmacokinetic interaction; possible slight increase in carbamazepine-epoxide | Monitor for carbamazepine toxicity symptoms (diplopia, ataxia) |
| Other antiepileptics (valproate, phenytoin, phenobarbital) | No significant pharmacokinetic interactions; may have additive CNS effects | Standard monitoring; generally safe combination |
| Warfarin | Theoretical interaction (not CYP-mediated) | Monitor INR when initiating or stopping levetiracetam |
| Antidepressants/Antipsychotics | Additive risk of behavioural adverse effects | Monitor mood and behaviour closely |
| Oral contraceptives | No enzyme induction — does not reduce contraceptive efficacy | Safe combination; no additional contraception required |
Common Adverse effects
- Somnolence / drowsiness
- Dizziness
- Asthenia / fatigue
- Irritability and behavioural changes
- Headache
- Nasopharyngitis / upper respiratory infections
- Decreased appetite
- Mood changes (anxiety, emotional lability)
Serious Adverse effects'
| Adverse Effect | Clinical Action |
|---|---|
| Severe behavioural disturbance (psychosis, aggression, hostility) | Consider dose reduction or discontinuation; psychiatric evaluation |
| Suicidal ideation or behaviour | Immediate psychiatric referral; consider drug discontinuation |
| Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis |
Immediate discontinuation and hospitalisation — rare but reported
|
| Anaphylaxis / Angioedema | Discontinue immediately; emergency management |
| DRESS syndrome | Rare; discontinue and supportive care |
| Pancytopenia / Agranulocytosis | Very rare; discontinue and investigate |
| Rhabdomyolysis | Rare; check CK if myalgia/weakness prominent |
Monitoring requirements
Baseline:
- Renal function (serum creatinine, eGFR)
- Seizure history and frequency documentation
- Psychiatric history assessment
- Pregnancy test in women of childbearing age
After Initiation / Dose Change:
- Mental status and behavioural assessment at 2–4 weeks
- Seizure frequency monitoring
- Assessment for irritability, mood changes (especially in children and adolescents)
- Evaluate for somnolence and cognitive effects
Long-term Monitoring:
- Renal function annually (more frequently in elderly or renal impairment)
- Behavioural and mood assessment at each visit
- Growth parameters in children
- Seizure diary review
- Periodic assessment of need for continued therapy
Note: Routine serum drug level monitoring not required — clinical response guides dosing. Therapeutic drug monitoring may be considered in pregnancy, renal impairment, or suspected non-adherence.
Brands in India
Single-Ingredient Formulations:
- Keppra (UCB)
- Levipil (Sun Pharma)
- Torleva (Torrent)
- Levera (Intas)
- Levesam (Mankind)
- Levroxa (Macleods)
- Epitero (Cipla)
- Levegard (Zydus)
Extended-Release Formulations:
- Levipil XR (Sun Pharma)
- Torleva XR (Torrent)
IV Formulations:
- Keppra IV (UCB)
- Levipil IV (Sun Pharma)
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Tablet 250 mg (per tablet) | ₹3–₹8 |
| Tablet 500 mg (per tablet) | ₹5–₹15 |
| Tablet 750 mg (per tablet) | ₹8–₹18 |
| Tablet 1000 mg (per tablet) | ₹10–₹22 |
| Oral Solution 100 mL | ₹150–₹300 |
| Injection 500 mg/5 mL (per vial) | ₹100–₹250 |
| Extended-Release tablets (per tablet) | ₹12–₹30 |
- Not currently included in NLEM 2022
- Available in government hospitals through neurology programmes
- Significant brand-to-brand price variation — generic options more affordable
Clinical pearls
- Preferred AED in hepatic impairment — minimal hepatic metabolism makes levetiracetam ideal for patients with liver disease or those on multiple hepatically metabolised drugs
- No enzyme induction — unlike carbamazepine and phenytoin, does not reduce efficacy of oral contraceptives, warfarin, or other CYP-metabolised drugs
- Behavioural adverse effects are common — especially irritability and aggression in children; counsel caregivers at initiation and monitor closely; pyridoxine (vitamin B6) supplementation sometimes used empirically to mitigate behavioural effects
- Seamless IV-to-oral transition — bioequivalent formulations allow direct 1:1 dose conversion without adjustment
- Gradual withdrawal essential — even in seizure-free patients, abrupt discontinuation may precipitate rebound seizures; taper over 2–4 weeks minimum
- Pregnancy-compatible AED — among the safer antiepileptics for use during pregnancy; preferred over valproate, phenytoin, and carbamazepine when new AED initiation required in women of childbearing potential
- Renal dosing mandatory in elderly — age-related decline in renal function often unrecognised; always calculate eGFR before prescribing
Version
RxIndia v1.0 — 05 Jun 2025
Reference
-
- CDSCO approved product inserts
- Indian Pharmacopoeia
- API Textbook of Medicine
- AIIMS Epilepsy Management Protocol
- ICMR Guidelines on Neurological Disorders
- IAP Paediatric Drug Formulary
- Indian Epilepsy Society recommendations
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (supportive)
- Harrison's Principles of Internal Medicine (supportive)
- International RCTs for off-label status epilepticus use
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.